United Kingdom Peptide Cancer Vaccine Market Size Analysis, Growth Trends & Forecast to 2034

United Kingdom Peptide Cancer Vaccine Market Overview 

The United Kingdom peptide cancer vaccine market is projected to expand from USD 0.43 billion in 2026 to USD 2.83 billion by 2034, registering a CAGR of 28.1% during 2026–2034. The peptide cancer vaccine sector in the UK is an underdeveloped niche within the cancer immunotherapy industry, with innovation focused on tumor antigen discovery, peptide engineering, and personalized medicine. There is strong potential for growth in the peptide cancer vaccine segment in the UK due to its highly developed scientific infrastructure in oncology. The UK market for peptide cancer vaccines is fueled by institutions such as the NHS, Cancer Research UK, and universities, as well as biotech companies working on vaccine-related research and development. In the future, the peptide vaccine market will likely mature with neoantigen vaccines based on tumor analysis developed on an individual patient basis, as well as off-the-shelf vaccines for universal cancer antigens. The economic constraints to the use of this technology include the high cost of producing customized vaccines, difficulties in vaccine development, and insufficient testing and demonstration of efficacy against complex cancer types.

United Kingdom Peptide Cancer Vaccine Market Growth Drivers

Growth in personalized cancer immunotherapy

Increased acceptance of personalized cancer therapy through immunotherapy is one of the significant factors driving the market for the development of peptide-based cancer vaccines within the UK. Indeed, tumor profiling and identification of neoantigens, as well as immune profiling, have been advancing, thereby facilitating vaccine formulation based on specific molecular aspects of a certain person's tumor. This becomes important for the creation of personalized peptide cancer vaccines, as such tumors' neoantigens may be identified and used for the production of vaccines stimulating a specific T-cell reaction. In May 2024, according to the journal Immunotherapy of Cancer, a clinical trial of the drug EVX-01 indicated the viability of a personalized cancer vaccine of peptide-based type, where neoantigens produced in a tumor were selected with the assistance of an AI platform, resulting in EVX-01-specific T-cells generated in patients with metastatic melanoma. At the same time, England has been developing infrastructure for practical use of such a strategy: In May 2024, NHS England mentioned that the first patient in England received a personalized cancer vaccine during a clinical trial; the NHS Cancer Vaccine Launch Pad uses patients' tumor tissue as well as blood samples to select patients for personalized treatment.

Strong NHS clinical-trial infrastructure and government support

The United Kingdom has a well-established clinical-trial system in the NHS, a wide network of cancer research organizations, advanced genome technologies, and government support for precision oncology technology. With access to a large patient population, unique cancer centers, high-quality tumor analysis, and established clinical trial networks, it becomes easier to identify patients, prove them in real-life settings, and generate evidence of the effectiveness of the treatment under investigation. Moreover, government-sponsored initiatives for cancer vaccine development and partnerships with biotechs enhance the whole community of cancer immunotherapies, promoting R&D funding and investment.

United Kingdom Peptide Cancer Vaccine Market Restraint

Limited clinical validation and manufacturing complexity

One of the most significant restraints to the growth of the UK market for peptide cancer vaccines is the limited clinical validation of products, as many of them are still being tested in the early stages of clinical trials and require more evidence of their efficacy, patient selection, and survival rates to be accepted by the market. The manufacturing process itself is also associated with its peculiarities; in the case of personalized peptide vaccines, there may appear additional challenges connected with identifying unique antigens, producing peptides, testing their quality, and manufacturing them in small batches according to GMP standards.

United Kingdom Peptide Cancer Vaccine Market Opportunities

The increasing emphasis on personalized cancer therapy presents an opportunity for the developers of peptide cancer vaccines in the UK to formulate vaccines that target patient-specific tumor antigens and genetics. Peptide vaccines can also be used in combination with immune checkpoint inhibitors and other immunotherapeutic drugs in order to enhance anti-tumor immune response and overcome resistance to single-drug therapies. The infrastructure available in the UK for precision oncology, genomics, and clinical trials by the NHS can help in identifying suitable patients for such therapies. This provides opportunities for pharmaceutical and biotech companies to differentiate their peptide vaccines, forge clinical collaborations, and enter the cancer segment where immunotherapy has its limitations.

United Kingdom Peptide Cancer Vaccine Market Scope

United Kingdom Peptide Cancer Vaccine Market Report Segmentation Analysis

The Personalized Peptide Vaccines Segment Is Expected to Dominate the United Kingdom Peptide Cancer Vaccine Market During the Forecast Period 

The personalized peptide vaccines segment is projected to continue dominating the market in the UK due to the growing uptake of precision oncology and developments in tumor genomics. Personalized vaccines can be developed to target neoantigens unique to each patient, in contrast to other conventional vaccines based on shared antigens. The UK's existing genomic testing capabilities, the infrastructure of NHS cancer research, and increasing clinical trial activities in personalized cancer vaccines are all propelling this sector. Growing interest from pharmaceutical and biotechnology companies in individualized immunotherapies is also pushing clinical development and partnerships, thereby establishing personalized peptide vaccines as a prominent trend in the UK peptide cancer vaccine market.

Melanoma Segment Is Expected to Dominate the United Kingdom Peptide Cancer Vaccine Market During the Forecast Period

The melanoma segment is positioned to remain a leading application area in the UK peptide cancer vaccine market, supported by melanoma’s strong immunogenicity and established responsiveness to immunotherapy. The presence of tumor-associated and melanoma-specific antigens provides opportunities for peptide vaccines to stimulate targeted anti-tumor immune responses. Growing research into peptide vaccines in combination with immune checkpoint inhibitors is also expanding clinical-development opportunities, particularly for patients with advanced or treatment-resistant melanoma. The UK’s strong oncology research base and NHS clinical-trial infrastructure further support the evaluation of novel melanoma vaccines, strengthening the segment’s potential during the forecast period.

The Hospital Segment Is Expected to Dominate the United Kingdom Peptide Cancer Vaccine Market During the Forecast Period

The hospital sector is projected to occupy a dominant market share in the United Kingdom peptide cancer vaccine market owing to the presence of cancer diagnosis, specialized oncology care, clinical research, and immunotherapy delivery in hospital settings. Peptide cancer vaccines are primarily used in clinical trials, investigational treatments, and specialized cancer treatments. Therefore, the hospital is the main venue for patient selection, biomarker testing, delivery of vaccines, and treatment response and adverse effects monitoring. The existing network of NHS hospitals and specialist cancer centers in the UK, which includes hospitals conducting clinical research on immunotherapy, offers the necessary platform for these treatments to develop from clinical studies to wider applications. Moreover, hospitals can combine peptide vaccines with other treatment options like chemotherapy, radiotherapy, immune checkpoint inhibitors, and targeted drugs, which increases their application in combination treatments. Thus, hospitals are expected to be the main application site of peptide cancer vaccines in the coming years.

The following segments are part of an in-depth analysis of the United Kingdom Peptide Cancer Vaccine Market:

United Kingdom Peptide Cancer Vaccine Market Competition Landscape Analysis

The UK peptide cancer vaccine market is still immature and research-oriented, with competition based more on clinical development, antigen/peptide technology, manufacturing capacity, and access to oncology trial networks rather than on commercial sales of products. The UK cancer vaccine industry comprises pharmaceutical companies, biotechnology firms, spinouts from universities, and NHS-based research programs. Though most of the leading programs employ mRNA and other non-peptide technologies, peptide-based companies play an important role in the industry, especially when it comes to therapeutic vaccines against tumor-associated antigens. The UK's clinical infrastructure of the UK is also becoming an important factor in competition, as NHS England's Cancer Vaccine Launch Pad is aimed at speeding up recruitment to cancer vaccine and immunotherapy trials, and Oxford has its own cancer vaccine hub covering antigen discovery, vaccine development, clinical manufacturing, and clinical trials.

United Kingdom Peptide Cancer Vaccine Market Recent Developments News:

• In June 2026, Talentmark highlighted the UK’s growing focus on personalized cancer vaccines, noting that Moderna’s personalized mRNA cancer vaccines for melanoma and other solid tumors were being fast-tracked through UK clinical trials. The development reflects increasing NHS, government, and biotech support for precision cancer vaccines and reinforces the UK’s role as an early clinical-development and potential launch market for next-generation cancer immunotherapies.

• In August 2025, researchers reported promising early results for ELI-002 2P, an off-the-shelf peptide cancer vaccine targeting common KRAS mutations associated with pancreatic and colorectal cancers. In a 25-patient study, the vaccine generated strong immune responses in 17 patients, with this group showing longer periods before recurrence and better overall survival than patients with weaker immune responses. Although the study was small and non-randomized, the findings support further development of scalable peptide-based cancer vaccines that could offer faster and potentially lower-cost access than personalized vaccines.  

The United Kingdom Peptide Cancer Vaccine Market is dominated by a few large companies, such as

• Scancell Holdings plc

• TREOS Bio Ltd.

• Oxford Vacmedix UK Ltd.

• Greenwich LifeSciences, Inc.

• IO Biotech, Inc.

• OncoTherapy Science, Inc.

• Shionogi & Co., Ltd.

• BrightPath Biotherapeutics Co., Ltd.

• Elicio Therapeutics, Inc.

• SELLAS Life Sciences Group, Inc.

• ISA Pharmaceuticals B.V.

• Imugene Limited

• VAXON Biotech

• OncoPep, Inc.

• Marker Therapeutics, Inc. 

• Other Prominent Players